Veeda Oncology selects TrialWorks by ClinPhone to further strengthen clinical trial management capabilities.
Nottingham, UK-May 19, 2008-ClinPhone (www.clinphone.com), a major Clinical Technology Organization (CTO), announces that Veeda Oncology, a specialist CRO, has selected TrialWorks by ClinPhone to further strengthen its clinical trial management capabilities.
Veeda Oncology (www.veedaoncology.com), a subsidiary of Veeda Clinical Research, will implement TrialWorks across its four major sites in India, France, Germany, and the US, providing international team members with real-time, immediate access to the company’s clinical trial management data and reports.
Speaking about the selection of TrialWorks, Kathy Squillace, vice president of global clinical operations at Veeda Oncology, stated, “One of our primary goals when establishing Veeda Oncology was to ensure we had a state-of-the-art infrastructure in place to effectively track, manage and report on our clinical data globally. Because our sites are spread geographically, we needed a web-based system that was intuitive and easy to use, while still offering robust functionality. TrialWorks emerged as the leader for us in this regard.”
Veeda Oncology had initially approached ten vendors, of which three matched their full user requirements. As well as the competitive price, it was the user interface and monitoring module that appealed to Veeda Oncology and ultimately led to their selection of TrialWorks. The monitoring module permits monitors to upload data remotely and produce monitoring reports in Microsoft Word format. TrialWorks, which is a web-based hosted or licensed solution, has strong functionality and is well-known for being very user-friendly and intuitive.
Squillace also added, “We’re confident that TrialWorks will not only save time for our monitors and site personnel, but will also provide significant support to our project managers, particularly in areas such as the tracking and management of investigator payments.”
TrialWorks is a powerful, user-friendly application designed to track, manage and report on virtually all day-to-day study management information. TrialWorks provides comprehensive trial management data, ranging from high-level consolidated metrics for senior managers to meaningful, drill-down reports to support project teams. The underlying relational database allows information to be grouped and filtered at various levels including trial, country, and site/investigator.
Ian Jennings, senior vice president of business development at ClinPhone, commented, “TrialWorks is a proven solution and has been used for thousands of trials by companies around the world. By implementing TrialWorks across Veeda Oncology sites and providing unrivaled customer service and support, we aim to offer the benefits of easier, faster and more efficient clinical trial management.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.